{
    "clinical_study": {
        "@rank": "128005", 
        "brief_summary": {
            "textblock": "RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the\n      tumor.\n\n      PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have\n      recurrent bladder cancer."
        }, 
        "brief_title": "Suramin in Treating Patients With Recurrent Bladder Cancer", 
        "completion_date": {
            "#text": "October 2007", 
            "@type": "Actual"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the maximum tolerated dose (MTD) of suramin in patients with recurrent\n           superficial bladder cancer.\n\n        -  Confirm that there is no significant systemic absorption of this drug when administered\n           intravesically in these patients.\n\n      OUTLINE: This is a dose escalation study.\n\n      At approximately 14-18 days after surgical resection of bladder tumor(s), patients receive\n      intravesicular suramin via urethral catheter installation into the bladder over 2 hours\n      weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.\n\n      Cohorts of 3-6 patients receive escalating doses of suramin until the maximum tolerated dose\n      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients\n      develop dose-limiting toxicity.\n\n      Patients are followed at 2-4 weeks.\n\n      PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study over 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically proven recurrent superficial bladder cancer\n\n               -  Intermediate prognosis as defined by the following:\n\n                    -  Recurrent, multiple Ta, T1 carcinoma\n\n                    -  Multiple (1-7) tumors\n\n                    -  Tumors resected previously must be histological grade G1 or G2 OR\n\n          -  Previously treated superficial bladder cancer requiring followup cystoscopy\n\n               -  Recurrent disease diagnosed at surgery\n\n          -  No tumor invasion into muscle or carcinoma in situ\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC at least 3,500/mm3\n\n          -  Platelet count at least 150,000/mm3\n\n        Hepatic:\n\n          -  No clinically significant hepatic disease\n\n        Renal:\n\n          -  Creatinine clearance greater than 60 mL/min\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 6 months after study\n\n          -  No history of adrenal insufficiency\n\n          -  No other malignancy within the past 5 years except adequately treated cone-biopsied\n             carcinoma in situ of the cervix or nonmelanoma skin cancer\n\n          -  No history of difficult catheterization\n\n          -  No confusion or disorientation\n\n          -  No other condition that would preclude study compliance\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent biologic therapy\n\n        Chemotherapy:\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  No concurrent corticosteroids\n\n        Radiotherapy:\n\n          -  No prior radiotherapy to the bladder\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior major thoracic or abdominal surgery\n\n        Other:\n\n          -  Recovered from prior therapy and stable for 4 weeks\n\n          -  At least 6 weeks since prior intravesicular therapy\n\n          -  No prior or concurrent investigational drugs\n\n          -  No concurrent anticoagulants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00006476", 
            "org_study_id": "CRC-PHASE I/II-PH1/073", 
            "secondary_id": [
                "CDR0000068303", 
                "NCI-954"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "suramin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "conventional surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Suramin"
        }, 
        "keyword": [
            "stage 0 bladder cancer", 
            "stage I bladder cancer", 
            "recurrent bladder cancer"
        ], 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oxford", 
                    "country": "United Kingdom", 
                    "state": "England", 
                    "zip": "0X3 9DU"
                }, 
                "name": "Oxford Radcliffe Hospital"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer", 
        "overall_official": {
            "affiliation": "Oxford University Hospitals NHS Trust", 
            "last_name": "Adrian L. Harris, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00006476"
        }, 
        "results_reference": {
            "PMID": "15928663", 
            "citation": "Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer. 2005 Jun 20;92(12):2140-7."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cancer Research UK", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2007"
    }, 
    "geocoordinates": {
        "Oxford Radcliffe Hospital": "51.752 -1.255"
    }
}